Skip to main content
NEO
NASDAQ Industrial Applications And Services

NeoGenomics closes DOJ probe with $9.8M settlement, coming in below its $11.2M reserve

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$14.24
Mkt Cap
$1.854B
52W Low
$4.72
52W High
$15.57
52W Position info
202% above low
Off High info
8.5% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

NEO has more than doubled off its 52-week low of $4.72.

Summary

NeoGenomics finalized a $9.8 million civil settlement with the DOJ and OIG-HHS, resolving a self-disclosed investigation into consulting services. The payment comes in below the $11.2 million reserve, potentially freeing up $1.4 million.


Key Events · Legal and Risk Events · NEO

  • DOJ Settlement Finalized at $9.8M

    To resolve a civil investigation into consulting services provided to healthcare providers, NeoGenomics agreed to pay $9,813,260 plus 4.25% annual interest from January 16, 2026.

  • Settlement Below Accrued Reserve

    The final settlement is approximately $1.4 million less than the $11.2 million the company had previously accrued for potential damages, which could result in a reserve release.

  • Legacy Investigation Closed

    Voluntarily self-disclosed to the OIG in November 2021, the matter is now resolved without admission of liability, removing a multi-year overhang.

  • CEO Comments on Resolution

    CEO Tony Zook stated the resolution allows the company to 'continue moving forward with its vision and commitment to advancing personalized cancer care.'


Analysis · NEO · Industrial Applications And Services

A years-long federal healthcare investigation has been resolved for $9.8 million — roughly $1.4 million less than the amount NeoGenomics had set aside. The payment removes a significant legal overhang that has lingered since the company self-disclosed the matter in 2021. While the cash outlay is modest relative to a $1.85 billion market cap, closing this legacy issue clears the way for management to refocus on its core oncology diagnostics business without the distraction and uncertainty of a DOJ probe.

At the time of this filing, NEO was trading at $14.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $4.72 to $15.57. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NEO - Latest Insights

NEO
Jul 20, 2026, 5:23 PM EDT
Source: BusinessWire
Importance Score:
7
NEO
Jun 25, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
NEO
Jun 22, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
NEO
Jun 17, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
8
NEO
Jun 15, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8